Market Intelligence, Clinical Progress, and High-Purity Reagents for Next-Generation Immunotherapy and Autoimmune Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CRTAM drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CRTAM ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View CRTAM Products |
| Gene Delivery | CRTAM Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and flow cytometry validation. |
View CRTAM Products |
| Benchmark Ab | Anti-CRTAM Recombinant Antibody Recombinant positive control for binding and functional blocking assays. |
View CRTAM Products |
| Validator | CRTAM siRNA Set For target knockdown validation in primary T cells or NK cells. |
View CRTAM Products |
| Related Target A | CADM1 (Necl-2) The primary physiological ligand of CRTAM. Crucial for establishing functional binding assays. |
View CADM1 Products |
| Related Target B | CD226 (DNAM-1) Synergistic co-stimulatory pathway partner involved in NK and CD8+ T cell activation. |
View CD226 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| CRTAM-CADM1 Interaction Screening | Human and mouse ortholog CRTAM and CADM1 ECD-Fc proteins with >95% purity for high-throughput SPR/BLI screening. |
| Cell-Based Conformation Verification | High-titer CRTAM Lentivirus for establishing stable reporter cell lines, preserving native folding and glycosylation. |
| Lack of Controls | Sequence-verified benchmark antibodies generated from clinical-stage leads for assay calibration. |
| Off-Target Cross-Reactivity | Homolog screening panels (including other nectin-like family members) strictly verified by MS and SDS-PAGE. |
Live CRTAM/CD355 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CRTAM/CD355 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies (mAbs) to multi-specific immune cell engagers and targeted antagonists. Originally identified as a cytotoxic T and NK cell-specific marker, CRTAM is now recognized as a pivotal checkpoint regulating the retention and activation of intraepithelial lymphocytes. As first-generation immunotherapies reach clinical maturity, the next wave of R&D is targeting the CRTAM-CADM1 axis to either amplify anti-tumor cytotoxicity in solid tumors or suppress pathological inflammation in autoimmune disorders such as colitis and respiratory tract allergies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonistic mAb | Biotech Startups, Academic Spin-offs | Solid Tumors (NSCLC, Melanoma) | Receptor Clustering Assay (Need high-purity, low-endotoxin ECD-Fc) |
| Antagonistic mAb / Decoy | Biopharmaceutical Corporates | Inflammatory Bowel Disease (IBD), Asthma | Ligand Blocking Validation (Need biologically active CADM1 recombinant protein) |
| Bispecific Engagers | Oncology-focused Biotechs | Hematological Malignancies | Dual-targeting Binding Kinetics (Need highly stable heterodimer screening tools) |